Our lead oncology drug candidate VB-111 (ofranergene obadenovec) is the first VTS™-based agent for cancer therapy.
VB-111 is a unique biologic agent that uses a dual mechanism to target solid tumors:
- Based on a non-integrating, non-replicating, Adeno 5 vector, it utilizes VBL’s proprietary Vascular Targeting System (VTS™) to target the tumor vasculature for cancer therapy. Unlike anti-VEGF or TKIs, VB-111 does not aim to block a specific pro-angiogenic pathway; instead, it uses an angiogenesis-specific sensor (VBL’s PPE-1-3x proprietary promoter) to specifically induce cell death in angiogenic endothelial cells in the tumor milieu. This mechanism may retain activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor and may show activity even after failure of prior treatment with other anti-angiogenics.
- Moreover, VB-111 induces specific anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells.
VBL Therapeutics’ pivotal Phase 3 OVAL trial of VB-111 in recurrent platinum-resistant ovarian cancer was launched in December 2017
Our OVAL phase 3 potential registration study of VB-111 in platinum resistant ovarian cancer is conducted in collaboration with the GOG Foundation, Inc., a leading organization for research excellence in the field of gynecologic malignancies. OVAL has been designed to enroll up to 400 adult patients at approximately 70 clinical sites in the United States and Israel. We plan to conduct an interim efficacy analysis of this trial in the fourth quarter of 2019 or the beginning of 2020.
VB-111 has received an orphan designation for the treatment of ovarian cancer by the European Medicines Agency.